


10 – 12 November, 2026 | Incheon

www.worldcgt-kr.com



World Cell & Gene Therapy Summit **SOUTH KOREA**

Engineering Scalable Cell & Gene Therapies from R&D to Commercial

Part of the World Advanced Therapeutics Summit South Korea by Hanson Wade

Accelerating Cell & Gene Therapies Through Innovative *In Vivo* & *Ex Vivo* Platforms, Targeted Delivery & Cost-Effective Manufacturing Towards Regulatory Harmonization in Oncology, Autoimmune & Beyond



80+
BIOPHARMA
ATTENDEES



20+
WORLD-CLASS
EXPERT SPEAKERS



35%
INTERNATIONAL
PRESENTERS



8+
HOURS OF
NETWORKING

World-Leading CGT Experts Include:



Peggy Sotiropoulou
Chief Scientific Officer
T-Knife Therapeutics



Gena Lee Meyers
Business Development Lead
Curocell



Je-Jung Lee
Chief Executive Officer
Vaxcell Bio



Tina Albertson
Chief Medical Officer
Caribou Biosciences



Minsung Choy
Director of Regulatory Affairs,
Cell Therapy
Legend Biotech



Aida Rouzmehr
Material Science Product Lead
Genentech

“ This meeting provides a valuable opportunity to share practical insights from successful and advanced cell and gene therapy leaders in Korea, while also learning from global leaders across the field ”

Gene Lee Meyers, Business Development Lead, **Curocell**

**LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY**

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



**REGISTER
NOW**

Accelerate Korea's Cell & Gene Therapy Industry from R&D to Commercial

연구개발부터 상업화까지 한국 세포·유전자 치료 산업 가속화

The cell and gene therapy (CGT) field is reaching a pivotal moment, driven by advances in *in vivo* therapies, improved LNP and AAV delivery systems, and increasing confidence in manufacturing to address scalability, cost, and development speed. This momentum is mirrored in South Korea's with milestones such as **Curocell's** Rimqarto becoming the first MFDS-approved cell therapy, and companies like **Vaxcellbio** and **Rznomics** developing novel platforms and modalities.

Created to accelerate this next wave of innovation, the inaugural **World Cell & Gene Therapy Summit South Korea** will unite world-class international and South Korean experts, to provide the most comprehensive lens on emerging CGT science and strategies towards clinical and commercial success for liquid and solid tumors, autoimmune diseases, and more.

Join 80+ CGT leaders, including **T-Knife Therapeutics**, **Bionoxx**, **Byterna Therapeutics** and more, to progress early proof-of-concept CAR-TCR, genome editing and RNA-based cell and gene therapies to patients faster.

World Cell & Gene Therapy Summit South Korea Team

Companies Presenting New Data Include:



iPS BIO

CUROCELL

GC Biopharma

tknife
THERAPEUTICS

VAXCELL



World Cell & Gene
Therapy Summit SOUTH KOREA

10 – 12 November, 2026 | Incheon

Key Benefits of Attending:

참석 주요 혜택:



Boost your R&D innovations from *in vivo* CAR, dual and triple-targeted engineering to gene editing breakthroughs to achieve clinical validation for oncology and autoimmune patients with insights from **Caribou Biosciences & GenomeFrontier Therapeutics**



Unearth key biological mechanisms of action data across T-, NK-, macrophage, and key cell therapy modalities to accomplish effective tumor targeting with insights from **KW-Bio & Vaxcell Bio**



Optimize your cargo delivery for *in vivo* CAR and gene editing programs from **LNP, AVV, and viral vectors** to reach specificity with insights from **Byterna Therapeutics & GC Biopharma**



Unlock global and South Korean CGT **supply chain and regulatory considerations** to help **streamline guidelines and submissions** for autologous and allogenic approaches, manufacturing, and CMC with insights from **Genentech & Legend Biotech**

**LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY**

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



**REGISTER
NOW**

2

+ (1) 617 455 4188

@ info@hansonwade.com

www.worldcgt-kr.com

www.worldadvanced-tx-kr.com

Cell & Gene Therapy Event Series

Cell Immunotherapy





Is Part Of:



LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

Reducing Vein-to-Vein Time in Oncology, Autoimmune & Beyond

The **World Cell & Gene Therapy Summit South Korea** is taking place as part of the **World Advanced Therapeutics Summit South Korea by Hanson Wade**, a co-located conference alongside the **2nd World RNA-Based Therapeutics & Vaccines Summit South Korea**.

With South Korea emerging as a global leader in innovation to develop first-and-best in- class cell, gene, and RNA-based therapeutics, the **World Advanced Therapeutics Summit South Korea by Hanson Wade** brings together these three hottest modalities, creating unparalleled opportunities for scientific progress and idea exchange, collaboration and networking to develop safer and more effective drugs with wider therapeutics windows.

Benefits of Attending a Co-Located Event

-  **Your registration provides access to both events**, meaning attendees can participate in sessions from other meetings at no additional charge (post-event content is only made available for the event you have registered for)
-  **Leverage cross-industry learnings and ensure comprehensive team coverage across all key content areas with up to 20% group discounts available regardless of the event selection**
-  **Expand your horizons and explore future pathways for your company's strategy with shared networking opportunities. Individual lanyards and badges onsite will show people's interests and expertise, for more targeted connections**

Plan Your Visit: What to Expect on Your Onsite Experience



Expected Audience Breakdown



CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



REGISTER
NOW

3

+ (1) 617 455 4188

@ info@hansonwade.com

www.worldadvanced-tx-kr.com

www.worldrna-kr.com

www.worldcgt-kr.com



Expert Speakers

전문가 연사

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

SCIENTIFIC ADVISORY BOARD



Peggy Sotiropoulou
Chief Scientific Officer
T-Knife Therapeutics

SCIENTIFIC ADVISORY BOARD



Gena Lee Meyers
Business Development
Lead
Curocell



Je-Jung Lee
Chief Executive Officer
Vaxcell Bio



Tina Albertson
Chief Medical Officer
Caribou Biosciences



Jeonghoon Han
Chief Executive Officer
Cunnovative



Mihue Jang
Principal Research
Scientist
Korea Institute of
Science & Technology



Heesoon Chang
Chief Executive Officer
KW-Bio



Gi-Hoon Nam
Chief Executive Officer
SHIFTBIO



Jihwan Song
Professor, Founder &
Chief Technology Officer
CHA University & iPS
Bio



Xian Zeng
Chief Executive Officer
Byterna Therapeutics



Seungryul Han
Head of R&D (Director)
Rznomics



Tae-Ho Hwang
Chief Technology Officer
Bionox



Juhi Verma
Manager
Micro CRISPR



Jiyeon Son
Team Leader
GC Biopharma



Bryan Choi
Professor
Inha University



Ting-Wan Lin
Director of Business
Development & Project
Manager
GenomeFrontier
Therapeutics



Donghyuk Jeon
Director of Production
Center
Curocell



Aida Rouzmehr
Material Science
Product Lead
Genentech



Cheng-Yi Jerry Kuo
Vice General Manager
UWELL Biopharma



Minsung Choy
Director of Regulatory
Affairs, Cell Therapy
Legend Biotech

“The summit is a premier global forum to exchange insights across Asia, the US and the EU, fostering the cross-regional collaborations essential to accelerating clinical innovation. It is an invaluable opportunity to shape the future of cell and gene therapy alongside the global scientific, biotech and pharma communities”

Peggy Sotiropoulou, Chief Scientific Officer, T-Knife Therapeutics

CONTENTS

- WELCOME
- WORLD
ADVANCED
THERAPEUTICS
SUMMIT
- SPEAKERS
- PRE-
CONFERENCE
DAY
- CONFERENCE
DAY ONE
- CONFERENCE
DAY TWO
- PARTNER
WITH US
- CO-LOCATED
EVENT
- PRICING &
DISCOUNTS



REGISTER
NOW



Check-In & Morning Coffee

8.30

Workshop A - Manufacturing

9.30

Building a Robust CMC Strategy for Cell & Gene Therapy Products to Ensure Safety Whilst Manufacturing Processes at Scaling With Cost Effectiveness

Cell and gene therapy development is advancing toward commercialization faster than most manufacturing, process development, analytical, and CMC teams can keep pace. This is especially evident as South Korea’s first CAR-T therapy enters the market.

Amid ongoing regulatory uncertainty, the primary challenge lies not in clinical performance but in supply chain and process readiness, making now a critical window to build robust, scalable, and compliant manufacturing strategies.

Join this workshop to gain key insights on:

- Systemic Agility: Mitigating material complexities and supply network volatility
- Clinical development of chimeric antigen receptor T-cell therapy manufacturing, formulation and administration
- Ensuring safety and cost efficiency in the scaled manufacturing of cell therapy products

Workshop Presenters



Donghyuk Jeon
Director of Production Center
Curocell



Aida Rouzmehr
Material Science Product Lead
Genentech



Cheng-Yi Jerry Kuo
Vice General Manager
UWELL Biopharma



Lunch Break

12.00



Networking Break

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA, cell and gene fields and establish meaningful business relationships ahead of the main conference days

12.45

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



REGISTER
NOW

Workshop B - Regulatory Affairs 13.30

Unlocking the Regulatory Landscape for Cell & Gene Therapies in South Korea & Globally to Expedite Market Entry

With Curocell’s Phase III cell therapy now market-approved in South Korea, the race is on to further advance more innovative treatment options. These must meet both regional and global regulatory criteria for CMC and clinical data packages, especially as more complex products enter development such as *in vivo* CAR-T, gene editing, autologous, and allogeneic approaches.

This workshop will gather experts to discuss:

- Understanding regulatory guidance on developing cell and gene therapies through pre-clinical model toxicity profile, safety study design patient recruitment and endpoints
- Reviewing phase-appropriate interactions with regulators for effective characterization of cell and gene therapies including identify, purity and control assays
- Addressing the common pitfalls when benchmarking quality attributes to regulatory standards and what data packages are required for South Korea, USA and across the globe

Workshop Presenters



Jeonghoon Han
Chief Executive Officer
Cunnovative



Bryan Choi
Professor
Inha University



Minsung Choy
Director of Regulatory Affairs,
Cell Therapy
Legend Biotech

End of Pre-Conference Workshop Day 16.00

■ The future of cell and gene therapy will be shaped by the convergence of programmable RNA medicines, targeted delivery, and *in vivo* cell engineering. The *World Cell & Gene Therapy Summit South Korea* provides a valuable platform for global leaders to exchange ideas on how to accelerate clinical translation, improve manufacturing efficiency, and expand patient access across oncology, autoimmune diseases, and beyond ■

Xian Zeng, Chief Executive Officer, Byterna Therapeutics

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day One | Wednesday, 11 November 2026

과학 프로그램 1 일 차

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



7.45 Check-In & Morning Coffee

8.45 Chair's Opening Remarks

Allogeneic, Autologous, & *In Vivo* – Showcasing the Progress of Cell Therapy Into Clinical & Commercial to Provide Better Treatment Options for Patients Faster



Gena Lee Meyers
Business Development Lead
Curocell

9.00 **Translating Domestic CAR-T Innovation Into Global Competitiveness: Insights From Korea's First BLA Approval**

- Unveiling the process and strategy in obtaining first domestic CAR-T therapy in Korea
- Sharing the commercialization and expansion plan for approved CAR-T therapy
- Outlining future development plans



Tina Albertson
Chief Medical Officer
Caribou Biosciences

9.30 **New Era in Allogeneic CAR-T: Genome-Engineered Cell Therapies Delivering on Scale, Durability, & Access**

- Exploring multi-edit allogeneic CAR-T engineering strategies, including checkpoint disruption and immune cloaking, designed to enhance persistence and antitumor activity
- Reviewing clinical data supporting durable efficacy, rapid treatment access, and scalable manufacturing across lymphoma and multiple myeloma programs
- Sharing the role of precision genome editing in enabling next-generation off-the-shelf cell therapies with the potential to broaden global patient access



Peggy Sotiropoulou
Chief Scientific Officer
T-Knife Therapeutics

10.00 **Engineering Next-Generation *In Vivo* “Off-the-Shelf” CAR-T Therapies to Overcome Barriers in Solid Tumors**

- Designing multi-armored T cell therapies to overcome tumor resistance mechanisms
- Engineering armored CAR and TCR constructs specifically optimized for *in vivo* cell therapies
- Advancing first- and best-in-class multi-armored *in vivo* cell therapies for solid tumors



10:30 **Networking Session**

Get face-to-face with many of the brightest minds working in the cell and gene therapy field and establish meaningful business relationships to pursue for the rest of the conference. As part of the World Advanced Therapeutics Summit South Korea, attendees will also be able to networking with experts working on the RNA field.

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



REGISTER
NOW

Conference Day One | Wednesday, 11 November 2026

과학 프로그램 1 일 차

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



11.00 Morning Coffee Break

Outlining the South Korean & Global CGT Roadmap to Advance Clinical Programs Towards Commercial Assets

11.30 Korean & Global Leaders Fireside Panel: Reviewing the Current Cell & Gene Therapy Landscape Towards Developing Scalable & Efficacious Drugs to Combat Cancer, Autoimmune Diseases & Beyond

Hear from executive leaders who will discuss their ambitions, strategies and challenges for the future cell and gene therapies, the hottest indications of unmet need and progress towards the next commercial approval, which include:

- What are the future opportunities, promising targets and applications on the horizon for cell and gene therapies to achieve clinical success?
- What are the current industry's top priorities and upcoming hurdles to development, such as investment, manufacturing, pricing and reimbursement and commercialization to better prepare and strategize to navigate the evolving landscape
- How to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your CAR-T, gene editing and therapeutic programs



Gena Lee Meyers
Business Development Lead
Curocell



Tina Albertson
Chief Medical Officer
Caribou Biosciences

12.00 Session Reserved for Program Partner



Je-Jung Lee
Chief Executive Officer
Vaxcell Bio



12.30 Innovative Cancer Immunotherapy Development

- Sharing how NK cell therapy combined with HAIC for advanced HCC Phase 2a results showing 68.75% ORR and 100% Disease Control Rate
- Showcasing how to best expand NK cell therapy to additional solid tumors, including small cell lung cancer (SCLC) and pancreatic ductal adenocarcinoma (PDAC), alongside emergency trial cases
- Unveiling next-generation CAR platforms, CAR-MILs for multiple myeloma and dual PD-L1/EphA2 CAR-T for solid tumors, designed to overcome antigen escape and immunosuppression



13.00 Lunch Break



14.00 Extended Networking

Network with fellow attendees to share scientific insights on cell and gene therapy development, as well as with global service providers and those working in the RNA field.

CONTENTS

- WELCOME
- WORLD
ADVANCED
THERAPEUTICS
SUMMIT
- SPEAKERS
- PRE-
CONFERENCE
DAY
- CONFERENCE
DAY ONE
- CONFERENCE
DAY TWO
- PARTNER
WITH US
- CO-LOCATED
EVENT
- PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day One | Wednesday, 11 November 2026

과학 프로그램 1 일 차

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

Achieving Shortened Vein-To-Vein Time: Exploring Methods to Manufacturing & Technology Innovations to Discover & Develop Cell Therapies



Juhi Verma
Manager
Micro CRISPR

14.30 Advancing Next-Generation CAR-T Therapies for Solid Tumors: Engineering Strategies, Translational Challenges & Functional Insights

- Exploring strategies for engineering next-generation CAR-T therapies for solid tumors
- Outlining process optimization approaches to shorten CAR-T manufacturing timelines while maintaining product quality and functionality
- Developing scalable and cost-effective CAR-T production workflows



Tae-Ho Hwang
Chief Technology Officer
Bionox

15.00 Decoding Post-Activation Immune Dynamics Beyond Conventional Phenotyping in Cell & Gene Therapy

- Introducing BN-IFS™, a functional immune interaction profiling platform beyond conventional phenotyping
- Presenting translational and clinical data on dynamic neutrophil-T cell interaction states during immunotherapy and virotherapy
- Discussing real-time immune monitoring for biomarker discovery and next-generation cell and gene therapy development



15.30 Afternoon Break & Scientific Poster Session

As the landscape of innovation is enabling scalable and cost-effective cell and gene therapies, it is more important than ever to collaborate and learn for the growth of this field. Join our dedicated poster session to share your latest data and have a first look into what your peers are working on.

Advances in Cell Therapies: Overcoming Engineering & Targeting Barriers for Different Cell Types

16.30 Roundtable Discussion: Aligning the Optimal Cellular Modality With the Right Indication to Maximize Patient Response: T Cells vs NK Cells vs Gamma-Delta T Cells

- Exploring how to leverage innate-like recognition of stress-induced antigens to defining indications where gamma-delta T cells offer superior tumor surveillance compared with NK and T cells, particularly in heterogeneous or immune-evasive tumors
- Identifying disease settings in which NK cells provide enhanced therapeutic benefit, including solid and liquid tumors through natural cytotoxicity and off-the-shelf compatibility
- Exploring combinatorial and multimodal strategies incorporating monoclonal antibodies, checkpoint inhibitors, cytokines, or other immunomodulators to amplify cellular immune responses, overcome tumor-mediated immunosuppression, and achieve more durable tumor eradication



Peggy Sotiropoulou
Chief Scientific Officer
T-Knife Therapeutics



Heesoon Chang
Chief Executive Officer
KW-Bio

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day One | Wednesday, 11 November 2026

과학 프로그램 1 일 차

World Cell & Gene
Therapy Summit SOUTH KOREA
10 – 12 November, 2026 | Incheon

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



Jihwan Song
Professor, Founder & Chief
Technology Officer
CHA University & iPS Bio

17.00 Toward Clinical Translation in Huntington’s Disease: An Integrated Small-Molecule & Cell Therapy Strategy

- Overview of iPS Bio’s translational strategy for Huntington’s disease, integrating disease-modifying small-molecule approaches with allogeneic iPSC-derived neural precursor cell therapy
- Exploring the preclinical development of iPS Bio’s therapeutic programs, including patient-derived iPSC disease models, *in vivo* efficacy studies, mechanism-of-action considerations, and translational biomarkers
- Revealing key challenges and opportunities in advancing Huntington’s disease therapeutics toward clinical translation, including CMC, safety, regulatory strategy, patient selection, and global collaboration



Heesoon Chang
Chief Executive Officer
KW-Bio

17.30 Next-Generation Allogeneic Macrophages: A Novel Cell Therapy Modality for Intractable Diseases

- Discussing the advantages of macrophages as an alternative cell therapy modality
- Highlighting the therapeutic landscapes of macrophage-based cell therapies



18.00 Chair’s Closing Remarks

18.15 End of Conference Day One

“The *World Cell & Gene Therapy Summit South Korea* provides an important platform to connect scientific innovation, clinical translation, manufacturing strategy, and investment perspectives in the rapidly evolving cell and gene therapy field”

Jihwan Song, Founder & Chief Technology Officer, iPS Bio

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS

REGISTER
NOW



8.00 Registration & Morning Coffee

8.45 Chair's Opening Remarks

Spearheading Circular RNA-LNP Cell Therapy Strategies for Durable *In Vivo* Programming & Clinical Validation



Xian Zeng
Chief Executive Officer
Byterna Therapeutics

9.00 Circular mRNA *In Vivo* CAR-T for Cancer & Autoimmune Diseases



- Sharing innovations in cmCAR and CollectLNP technology enable a differentiable and highly extensible *in vivo* cell engineering platform
- Revealing how BR101, a bi-specific *in vivo* CAR-T pipeline based on cmCAR and CollectLNP, exhibits robust and systemic B-cell depletion and immune-reset in NHP
- Exploring how an open-label, single-arm clinical trial has been initiated to evaluate safety and efficacy of BR101 in cancer and autoimmune diseases



Jiyeon Son
Team Leader
GC Biopharma

9.30 Development of Lipid Nanoparticles for Precision mRNA Delivery: Advancing From Protein Replacement to *In Vivo* Genome Editing & CAR-T Cell Programming



- Rational Design of Ionizable Lipid Libraries: Application of Structure-Activity Relationship (SAR) modeling and AI-guided molecular design to develop a proprietary lipid library with an optimized therapeutic index and enhanced clinical tolerability
- Optimization for Hepatic Genome Editing: Identification and selection of LNP formulations tailored for high-efficiency hepatic delivery, facilitating the technical transition from transient protein replacement to permanent genetic intervention with minimal off-target toxicity
- Strategic Engineering for *in vivo* CAR-T Programming: Development of LNP formulations specifically optimized to maximize T-cell delivery efficiency, enabling precise *in vivo* CAR-T cell programming through systemic mRNA delivery



Mihue Jang
Principal Research Scientist
Korea Institute of Science
& Technology

10.00 Non-Viral CAR NK Platforms for Broad Therapeutic Applications in Cancer & Beyond

- Advancing non-viral CAR-NK platforms: Development of mRNA and circRNA-based CAR-NK systems enabling rapid, scalable, and safer manufacturing compared to viral approaches
- Overcoming key barriers in solid tumors: Strategies to address antigen shedding (e.g., MSLN), CAR downregulation, and TME-mediated suppression (including TGF-Beta resistance and metabolic reprogramming)
- Expanding therapeutic scope beyond oncology: Application of engineered NK cells in non-malignant diseases, highlighting next-generation targets and translational opportunities



10:30 Networking Session

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the cell, gene and mRNA fields and establish meaningful business relationships.

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day Two | Thursday, 12 November 2026

과학 프로그램 2 일 차

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



11.00 Morning Coffee Break

Next-Generation CAR-T Targeting Strategies to Overcome the Tumor Microenvironment & Enhance Infiltration



Ting-Wan Lin
Director of Business
Development & Project
Manager
GenomeFrontier Therapeutics

11.30 Early Clinical Validation of GF-CART01: A Non-Viral Dual-Targeting CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies

- Introducing Quantum Engine for non-viral gene therapy
- Describing the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Presenting preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell hematologic cancers



Jeonghoon Han
Chief Executive Officer
Cunnovative

12.00 Engineering Next-Generation CAR-T: Dual & Triple Targeting Strategies for Superior Clinical Outcomes

- Developing a dual-target CAR-T therapy for AML aimed at overcoming antigen heterogeneity and antigen escape–driven relapse
- Sharing insights about GPC3-targeted, multi-modal CAR-T therapy for hepatocellular carcinoma (HCC) to overcome the immunosuppressive tumor microenvironment, enhance T-cell persistence and infiltration, recruit endogenous bystander T cells



12.30 Lunch Break



13.15 Extended Networking

Optimizing Design, Delivery & Development of Effective Gene Therapies Tackling Common & Rare Diseases



Seungryul Han
Head of R&D (Director)
Rznomics

14.00 RNA Editing Based Gene Therapy Strategy Using Trans-Splicing Ribozyme

- Overview of RNA editing based on trans-splicing ribozyme
- Presenting cancer gene therapy
- Showcasing gene therapy for genetic disorders

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day Two | Thursday, 12 November 2026

과학 프로그램 2 일 차

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



Gi-Hoon Nam
Chief Executive Officer
SHIFTBIO



- 14.30**
- Crossing the Blood-Brain Barrier With Engineered Natural Nanoparticles: A Dock-&-Transcytose Approach for Deep Parenchymal Delivery of ASO, siRNA, & Protein Cargos**
- Presenting the NNP Trinity platform, a structure-prediction-driven approach that combines an NSM membrane-engineering scaffold, AI-guided design of protein assembly, and a validated 3D bioreactor process for scalable, clinical-grade production of cell-derived natural nanoparticles
 - Exploring the B-NNP brain shuttle, a dock-and-transcytose dual-targeting design in which Transferrin Receptor 1 drives receptor-mediated transcytosis across the blood-brain barrier while a second motif anchors the particle to a diseased-brain glycoprotein, enabling deep parenchymal delivery rather than perivascular accumulation
 - Outlining applied oligonucleotide delivery with *in vivo* data on ASO and siRNA cargo loaded into B-NNP, including amyloid-beta reduction in a 5XFAD Alzheimer's model after systemic IV dosing, with extension to additional CNS targets

15.00

Chair's Closing Remarks

15.15

End of Inaugural *World Cell & Gene Therapy Summit South Korea* & the *World Advanced Therapeutics Summit South Korea* by Hanson Wade

“This meeting provides an excellent opportunity to discuss emerging approaches in functional immune monitoring and translational immunology for cell and gene therapy”

Tae-Ho Hwang, Chief Technology Officer, **Bionox**

CONTENTS

WELCOME
WORLD ADVANCED THERAPEUTICS SUMMIT
SPEAKERS
PRE- CONFERENCE DAY
CONFERENCE DAY ONE
CONFERENCE DAY TWO
PARTNER WITH US
CO-LOCATED EVENT
PRICING & DISCOUNTS

**REGISTER
NOW**

Your Partnership Opportunities

파트너십 안내

Position Yourself as the Leading Cell & Gene Therapy Partner for Drug Development in South Korea

With Curocell securing South Korea's first domestic CAR T approval, the market is opening rapidly, reigniting both domestic and international interest in cell and gene therapies across the region, driving increased demand for specialized solution providers and new licensing opportunities.

The **World Cell & Gene Therapy Summit South Korea** is your premium opportunity to align your brand with leading Korean and global biotech and pharma experts actively seeking high-level support from trusted, local, and qualified CDMOs, distributors, and solution providers.

They are looking for expertise across pre-clinical model providers, analytical development experts, LNP and viral vector delivery technologies, CRO services, raw material suppliers and more.

This is a rare opportunity for you and/or your distributors to meet key CGT decision-makers face-to-face, build relationships, and expand your business into South Korea.

Why Partner?



Engage with 80+ attendees from Korean and global biopharma solely dedicated to CGT, a market that puts greater importance on in-person meetings



Establish brand credibility and highlight your services in this emerging market to ensure long-term success



Showcase how your services support innovation differentiation, and support novel cell, gene, and RNA therapies from discovery through to manufacturing



World Cell & Gene
Therapy Summit SOUTH KOREA

10 – 12 November, 2026 | Incheon

**LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY**

Partnership Opportunities Include:



Deliver high-impact, data-driven presentations that position your CGT capabilities as critical solutions for accelerating therapeutic development



Maximize brand visibility through onsite and digital exposure, placing your company at the center of the fast-growing CGT innovation ecosystem in South Korea



Host exclusive networking events (breakfasts, lunches, dinners) to showcase your solutions to senior decision-makers actively investing in novel CAR-T, NK-Cell, CRISPR technologies and beyond



Exhibit your innovations and technologies with a booth to attract prospects seeking partnerships, collaborations and licensing deals



Leverage exclusive access to the full delegate list to identify, target, and pre-book meetings with key stakeholders

Partnership Team



Kieran Crewe
Partnerships Manager



Charlotte Hodgson
Partnerships Manager

EU Tel: +44 203 141 8700 | **US Tel:** +1 415 735 3289
Email: sponsor@hansonwade.com

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



**REGISTER
NOW**

Your Additional Partnership Benefits

추가 파트너십 혜택



World Advanced
Therapeutics Summit SOUTH KOREA
by hansonwade

10 – 12 November, 2026 | Incheon

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

With many service providers actively avoiding business in China due to cost competitiveness, and Japan's biotech landscape remaining relatively small, South Korea is emerging as a key market for international players seeking to expand business in the APAC region in 2026.

As part of the **World Advanced Therapeutics Summit South Korea by Hanson Wade**, the **World Cell & Gene Therapy Summit South Korea** is co-located with the **2nd World RNA-Based Therapeutics & Vaccines Summit South Korea**.

By partnering with one or both events, you can tailor your presence to the specific communities where you want to position your organization as a leading service provider. Partners benefit from a shared exhibition space and the ability to engage with attendees across all co-located summits, creating efficient exposure to multiple audiences within the advanced therapeutics ecosystem. All packages will be custom made, while ensuring visibility to the broader attendee base.

Partnership Opportunities Include:



Speaking Opportunities



Exhibition Booths &
Networking



Event Branding



Business Intelligence



Hosted Lunches & Drinks
Reception



160+
Attendees



12+
Exhibitors



30+
Korean Biopharma
Companies




44%
Korean
Audience




56%
Rest of World including
USA, Europe & APAC


Attendees by Company Type*:



Attendees by Seniority*:



Attendees by Location*:



*Statistics Taken From the inaugural World RNA-Based Therapeutics & Vaccines Summit South Korea

CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



REGISTER
NOW

Discover the Event Happening Alongside:



World Advanced
Therapeutics Summit SOUTH KOREA
by hansonwade

10 – 12 November, 2026 | Incheon

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY



2nd Annual

World RNA-Based Therapeutics & Vaccines Summit SOUTH KOREA

Accelerating mRNA's Potential Across Infectious, Rare & Personalized Therapies

Developing Safe & Efficacious mRNA, CircRNA & SaRNA Medicines With Smarter Design Optimization, Targeted Delivery & Scalable Manufacturing for Clinical & Commercial Readiness

From **GC Biopharma** and **EyeGene's** momentum in mRNA vaccine clinical trials, and the launch of the ARPA-H PAVE Project to accelerate personalized mRNA cancer immunotherapies, the South Korean mRNA ecosystem is experiencing a powerful surge in innovation supported by government funding. This is driving safer, more effective mRNA medicines for patients across the region.

To spotlight this rapid progress, the **2nd World RNA-Based Therapeutics & Vaccines Summit South Korea** will deliver cutting-edge insights across next-generation mRNA design, therapeutic pipeline advancements, targeted delivery breakthroughs, and solutions, providing the benchmarks needed to propel these medicines forward.

Join 90+ leading players from **Aston Science**, **LG Chem**, **MediciBio**, and more, from C-Suite to Scientists across R&D, manufacturing, and business development, to help turn cutting-edge mRNA science into commercial reality.

For more information visit: www.worldrna-kr.com

Key Topics Include:

Optimizing mRNA sequence design across circular, self-amplifying and linear modalities to improve therapeutic efficacy

Turbocharging the clinical progress of RNA technology for *in Vivo* CAR, and gene editing technologies to achieve robust therapies with wider therapeutic potential

Achieving the best LNP composition and platform to ensure organ-specific targeting, tolerability and safety

Accelerating mRNA process development, CMC, and manufacturing to enable successful domestic and global production efficiently

Overcoming challenges for the development of mRNA personalized cancer immunotherapies with scalability, speed, and artificial intelligence

Building new alliances and strategic partnerships in the mRNA field with South Korean and global leaders

Speaking Companies Include:



CONTENTS

WELCOME

WORLD
ADVANCED
THERAPEUTICS
SUMMIT

SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER
WITH US

CO-LOCATED
EVENT

PRICING &
DISCOUNTS



REGISTER
NOW

Pricing & Registration

가격 및 등록

3 Easy Ways To Book

 www.worldcgt-kr.com/register

 Tel: +1 617 455 4188 | +44 0203 141 8700

 Email: info@hansonwade.com

Drug Developer & Platform Tech Pricing*	Lowest Ever Rates End 10 July	On the Door
Conference + 2 Workshops	\$1,599 (Save \$600)	\$2,199
Conference + 1 Workshop	\$1,399 (Save \$600)	\$1,999
Conference Only	\$1,199 (Save \$600)	\$1,799

Academia, Not-for-profit & Government Institute Pricing**	Lowest Ever Rates End 10 July	On the Door
Conference + 2 Workshops	\$1,299 (Save \$600)	\$1,899
Conference + 1 Workshop	\$1,149 (Save \$600)	\$1,749
Conference Only	\$999 (Save \$600)	\$1,599

Service Provider Pricing***	Lowest Ever Rates End 10 July	On the Door
Conference + 2 Workshops	\$4,049 (Save \$1,100)	\$5,149
Conference + 1 Workshop	\$3,649 (Save \$850)	\$4,499
Conference Only	\$3,249 (Save \$600)	\$3,849

All prices shown in USD.
All presentations in English.
With any pass, attendees receive immediate access to the full range of events at the *World Advanced Therapeutics Summit South Korea by Hanson Wade*. Post-event content is only made available for the event you have registered for.
* To qualify for the drug developer & platform tech pricing, your company must have a public drug pipeline or a platform technology intended for internal pipeline development or cross-licensing deals, and must not provide fee-based platforms or services. Please visit the website for full pricing options or email info@hansonwade.com
**To qualify for the academic rate, you must be a full-time academic. Please visit the website for full pricing options or email info@hansonwade.com
Do you work for a not-for-profit organization? Email us at info@hansonwade.com to enquire about attending
***If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Email sponsor@hansonwade.com to learn more

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities,tag, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Conferences Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Team Discounts

- 10% Discount – 2 Attendees
- 15% Discount – 3 Attendees
- 20% Discount – 4+ Attendees

**Please note that discounts are only valid when two or more delegates from one company book and pay at the same time for the same or both events.
Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.
Contact: register@hansonwade.com

- ① **UNLOCK** the latest progress in CGT development across South Korea to combat oncology, autoimmune conditions and beyond.
- ② **ACCELERATE** your strategies from T-, NK-, CRISPR, Macrophage and Stem Cell methods to overcome biological efficacy challenges and achieve clinical success.
- ③ **NETWORK** with 80+ leading cell and gene therapy developers from South Korea, China and across the world to seeking co-development, collaboration and licensing opportunities.

LOWEST-
EVER RATES
EXPIRING ON
FRIDAY, 10
JULY

CONTENTS
WELCOME
WORLD ADVANCED THERAPEUTICS SUMMIT
SPEAKERS
PRE- CONFERENCE DAY
CONFERENCE DAY ONE
CONFERENCE DAY TWO
PARTNER WITH US
CO-LOCATED EVENT
PRICING & DISCOUNTS

Venue

Grand Hyatt Incheon

208 Yeongjonghaeannam-ro 321beon-gil,
Jung-gu, Incheon, South Korea

Visit Website